Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Cash from Operations (2023 - 2026)

ArriVent BioPharma has reported Cash from Operations over the past 4 years, most recently at 41892000.0 for Q1 2026.

  • Quarterly results put Cash from Operations at 41892000.0 for Q1 2026, up 38.4% from a year ago — trailing twelve months through Mar 2026 was 134472000.0 (down 12.44% YoY), and the annual figure for FY2025 was 160588000.0, down 128.72%.
  • Cash from Operations reached 41892000.0 in Q1 2026 per AVBP's latest filing, down from 30658000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 8606000.0 in Q2 2023 and bottomed at 68008000.0 in Q1 2025.
  • Median Cash from Operations over the past 4 years was 18628000.0 (2024), compared with a mean of 25271846.15.
  • The largest annual shift saw Cash from Operations plummeted 265.08% in 2025 before it soared 38.4% in 2026.
  • Over 4 years, Cash from Operations stood at 14913000.0 in 2023, then dropped by 8.31% to 16152000.0 in 2024, then tumbled by 89.81% to 30658000.0 in 2025, then tumbled by 36.64% to 41892000.0 in 2026.
  • Business Quant data shows Cash from Operations for AVBP at 41892000.0 in Q1 2026, 30658000.0 in Q4 2025, and 35798000.0 in Q3 2025.